About Us

Eterna Therapeutics, is a publicly traded, preclinical-stage company focused on using cutting-edge gene-editing tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Our core technology utilizes best-in-class approach to engineer allogenic induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). We seek to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. Currently, we are focusing on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.

Eterna entered into an exclusive license and collaboration agreement with Factor Bioscience Limited in September 2024 and with this agreement, Eterna is transforming itself to a product-based developmental stage company.

Vision

At Eterna, our vision is to improve the lives of patients with difficult-to-treat diseases through innovative, effective, safe, and accessible synthetic induced mesenchymal stem cell (iMSC) therapies

Mission

Eterna is focused on developing off-the-shelf synthetic iMSCs to target solid tumors and inflammatory diseases